Entrada Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 5, 2026, covering the fiscal quarter ended June 30, 2026.

Key Highlights

  • Filing period: Quarterly report covers the three months ended June 30, 2026.
  • Shares outstanding: As of July 31, 2026, the company had 38,936,669 shares of common stock, par value $0.0001 per share, outstanding.
  • Exchange listing: Common stock trades on The Nasdaq Global Market under the ticker TRDA.
  • Filer status: The company reported it is an accelerated filer, a smaller reporting company, and an emerging growth company under SEC definitions.
  • EEV Platform: The filing references the company's proprietary EEV Platform as central to its therapeutic candidate development strategy.
  • Shell company status: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

Entrada Therapeutics Reports Q2 2026 Quarterly Financial Filing

Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company headquartered at One Design Center Place, Suite 17-500, Boston, MA 02210, submitted its quarterly report covering the period ended June 30, 2026. The filing was made under Commission File Number 001-40969. According to the filing, the company is incorporated in Delaware and carries an IRS Employer Identification Number of 81-3983399.

The filing describes Entrada Therapeutics as a company engaged in research and development of therapeutic candidates, with its proprietary EEV Platform cited as the mechanism through which it seeks to develop and advance those candidates. According to the filing, the company's forward-looking disclosures address areas including preclinical studies, clinical trial initiation and progress, regulatory filings, manufacturing scale-up, and collaboration arrangements. The filing notes these statements involve "known and unknown risks, uncertainties and other factors" and are subject to the cautionary language included in the Quarterly Report.

The registrant confirmed it filed all required reports during the preceding 12 months and submitted all required Interactive Data Files electronically pursuant to Rule 405 of Regulation S-T. The company elected emerging growth company status but did not indicate it has elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.

What Was Disclosed

Entrada Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, disclosing 38,936,669 shares of common stock outstanding as of July 31, 2026, its accelerated and emerging growth company filer status, and its reliance on the proprietary EEV Platform for therapeutic development activities.